Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emraclidine PET Target Occupancy Study
NCT04787302Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Jun 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of emraclidine in schizophrenia, sponsored by Cerevel Therapeutics. Primary endpoint: M4 receptor occupancy in the striatum at Day 1. Started Jun 2021; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04787302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787302.